Efficacy of rapid IV administration of valproic acid for status epilepticus.

Although not approved by the US Food and Drug Administration for the treatment of status epilepticus (SE), valproic acid (VPA) is an emerging option for this purpose. The authors reviewed 63 patients (30 men) with SE treated with IV VPA (average dose, 31.5 mg/kg). Analysis of demographic, clinical, and treatment information indicated an overall efficacy of 63.3% and favorable tolerance of rapid administration.
AuthorsN A Limdi, A V Shimpi, E Faught, C R Gomez, J G Burneo
JournalNeurology (Neurology) Vol. 64 Issue 2 Pg. 353-5 (Jan 25 2005) ISSN: 1526-632X [Electronic] United States
PMID15668440 (Publication Type: Journal Article, Review)
Chemical References
  • Anticonvulsants
  • Valproic Acid
  • Anticonvulsants (administration & dosage, therapeutic use)
  • Comorbidity
  • Drug Administration Schedule
  • Drug Evaluation
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Retrospective Studies
  • Status Epilepticus (drug therapy)
  • Treatment Outcome
  • Valproic Acid (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: